Experiences with a New High-Dose-Rate Brachytherapy (HDR-BT) Boost Technique for T3b Prostate Cancer

Rades, Dirk; Schwarz, Rudolf; Todorovic, M.; Thurmann, H.; Graefen, Markus; Walz, Jochen; Schild, Steven E.; Dunst, Juergen; Alberti, Winfried

doi:10.1007/s00066-007-1643-z

Cited by 13 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the risk for rectal and bladder tumors is increased after radiotherapy for cervix cancer [17]. In these circumstances, a reduction of late effects, e.g., by more conformal treatments [16,19,21], may reduce the risk for second cancers.…”

Section: Induction and Manifestation Of Second Tumorsmentioning

confidence: 99%

Second Tumors after Oncologic Treatment

Dörr

Herrmann

2008

Strahlenther Onkol

View full text Add to dashboard Cite

Radiotherapy results in a small but significant increase in tumor incidence, i.e., in secondary tumors. This is only relevant, if tumor cure is achieved with the first treatment. Collection of data on second tumors requires lifelong follow-up and/or a consequent documentation in cancer registries. The improvement in survival rates by successful radiotherapy clearly outweighs the reduction of survival by the induction of second tumors. Moreover, latent times for second neoplasms range from years to decades, while the survival after ineffective treatment is substantially shorter. Hence, the administration of ionizing radiation (in the case of clinically proven indications) is justified. Radiotherapy would even be warranted, if the incidence of second tumors were clearly higher than currently estimated, based on the difference in survival times for second tumors versus recurrences.

show abstract

Section: Induction and Manifestation Of Second Tumorsmentioning

confidence: 99%

Second Tumors after Oncologic Treatment

Dörr

Herrmann

2008

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

“…Palladium-103 seeds are also used for prostatic brachytherapy [17]. A simple estimate based on a comparable application procedure indicates that palladium seeds are likely to expose the finger sides about 50% higher than iodine-125 seeds.…”

Section: Dependencies Of the Measured Dosementioning

confidence: 99%

“…The standard radiotherapeutic approach to the treatment of localized tumors of the prostate has changed dramatically over the past 20 years [17]. The reasons are the increase in the proportion of low-risk cancers and new treatment techniques [26].…”

Section: Introductionmentioning

confidence: 99%

Exposure of Treating Physician to Radiation during Prostate Brachytherapy Using Iodine-125 Seeds

et al. 2009

View full text Add to dashboard Cite

Background and Purpose: Only sparse reports have been made about radiation exposure of the treating physician during prostate seed implantation. Therefore, thermoluminescence dosimeter (TLD) measurements on the index fingers and the backs of both hands were conducted. Material and Methods: Stranded iodine-125 seeds with a mean apparent activity of 27.4 MBq per seed were used. During application, the treating physician manipulated the loaded needle with the index fingers, partially under fluoroscopic control. Four physicians with varying experience treated 24 patients. The radiation exposure was determined with TLD-100 chips attached to the index fingertips and the backs of hands. Radiation exposure was correlated with the physician's experience.

show abstract

“…Patients with intermediate risk prostate cancer can be treated with a combination of interstitial brachytherapy (e.g., iodine-125 [ 125 I] seed implantation) and EBRT (external-beam radiation therapy) [11,21,26]. Prostate position during EBRT is influenced by daily variations of bladder and rectum filling [8,10,12,19].…”

Section: Introductionmentioning

confidence: 99%

Phantom Measurements to Quantify the Accuracy of a Commercially Available Cone-Beam CT Gray-Value Matching Algorithm Using Multiple Fiducials

Köhler¹,

Boda-Heggemann

Küpper³

et al. 2009

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

Experiences with a New High-Dose-Rate Brachytherapy (HDR-BT) Boost Technique for T3b Prostate Cancer

Abstract: The new HDR-BT technique (group B) was associated only with minor acute and late toxicity and appears to result in better bRFS than the conventional HDR-BT technique (group A). The results must be confirmed in a prospective trial.

Cited by 13 publications

References 18 publications

Second Tumors after Oncologic Treatment

Second Tumors after Oncologic Treatment

Exposure of Treating Physician to Radiation during Prostate Brachytherapy Using Iodine-125 Seeds

Phantom Measurements to Quantify the Accuracy of a Commercially Available Cone-Beam CT Gray-Value Matching Algorithm Using Multiple Fiducials

Contact Info

Product

Resources

About